No Data
No Data
Dian Diagnosis (300244.SZ): Currently, the first overseas medical testing laboratory opened in Vietnam on April 19, 2024
On May 16, Ge Longhui | Dian Diagnosis (300244.SZ) said at the performance briefing that the company's first overseas medical testing laboratory has now opened in Vietnam on April 19, 2024. You can follow the company's regular reports on overseas business revenue.
Dean Diagnosis (300244) Review Report: Good receivables trend, ICL grew steadily in the first quarter
Incident: Recently, the company released its 2023 annual report: annual revenue of 13.408 billion yuan, a year-on-year decrease of 33.89%, mainly due to a decrease in testing demand related to public health events and a sharp decline in the company's diagnostic service revenue
Dean Diagnosis (300244): Short-term performance is under pressure, ICL growth is steady
Key points: Revenue fell 33.89% year on year, net profit after deducting non-return to mother fell 81.90% year on year incident: Recently, the company released its 2023 annual report and 2024 quarterly report. In 2023, the company achieved operating income of 134.
Dian Diagnosis (300244.SZ) has repurchased a total of 5,529,500 shares at a cost of 100 million yuan
Zhitong Finance App News, Dean Diagnosis (300244.SZ) announced that as of April 30, 2024, the company had repurchased 5,529,500 shares of the company's shares through a dedicated securities account, accounting for 0.88% of the company's current total share capital. The highest transaction price was 18.91 yuan/share, the minimum transaction price was 15.01 yuan/share, and the total transaction amount was RMB 100 million (excluding transaction fees).
Dean Diagnosis (300244): Impairment calculation affects apparent performance First quarter results are lower than expected
Event: The company released its report for the first quarter of 2024. In the first quarter of 2024, it achieved operating income of 2,973 billion yuan (-8.01%), net profit to mother of 0.23 million yuan (-85.54%), deducting non-net profit
Huaan Securities released a research report on April 28 stating that it gave Dian Diagnosis (300244.SZ) a purchase rating. The main reasons for the rating include: 1) short-term performance is under pressure, and the scale effect remains the same; 2) regu
Huaan Securities released a research report on April 28 stating that it gave Dian Diagnosis (300244.SZ) a purchase rating. The main reasons for the rating include: 1) short-term performance is under pressure, and the scale effect remains the same; 2) regular business continues to grow, and the growth rate of special inspection business is stable. (Mainichi Keizai Shimbun)
No Data